Vivimed Labs Ltd

Vivimed Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vivimed Labs Ltd

₹ 4.95 -1.00%
31 Jul 2023
vivimedlabs.com BSE: 532660 NSE: VIVIMEDLAB
About

Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.[1]

Key Points

API Division (~69% of revenues)[1]
This is the flagship division of the company which is primarily managed by its subsidiary UQUIFA s.a. based in Spain. The division further has 2 sub-divisions :-[2]

Website BSE NSE - BZ
  • Market Cap ₹ 41.0 Cr.
  • Current Price ₹ 4.95
  • High / Low ₹ /
  • Stock P/E
  • Book Value ₹ 10.8
  • Dividend Yield 0.00 %
  • ROCE -7.41 %
  • ROE -34.6 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.46 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -11.5% over past five years.
  • Promoter holding is low: 20.9%
  • Company has a low return on equity of -48.4% over last 3 years.
  • Contingent liabilities of Rs.116 Cr.
  • Company might be capitalizing the interest cost
  • Promoters have pledged 37.1% of their holding.
  • Company has high debtors of 159 days.
  • Promoter holding has decreased over last 3 years: -7.64%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
62 35 62 51 52 53 47 39 51 40 33 30 37
49 55 51 62 59 55 56 49 57 203 33 36 36
Operating Profit 14 -20 11 -11 -7 -2 -9 -10 -6 -164 -0 -5 1
OPM % 22% -58% 17% -21% -14% -3% -18% -25% -12% -412% -1% -18% 2%
2 2 1 0 -0 1 0 0 0 0 0 2 0
Interest 11 9 9 9 12 10 9 9 9 8 11 12 13
Depreciation 4 4 4 4 4 5 4 4 4 95 4 4 4
Profit before tax 0 -32 -2 -23 -24 -16 -22 -22 -19 -267 -15 -20 -17
Tax % 0% -1% 0% 0% 0% 18% -0% 0% 0% -1% 0% 0% -3%
0 -31 -2 -23 -24 -19 -22 -22 -19 -265 -15 -20 -16
EPS in Rs 0.02 -3.78 -0.25 -2.83 -2.85 -2.24 -2.64 -2.67 -2.31 -31.94 -1.85 -2.36 -1.95
Raw PDF
Upcoming result date: 10 January 2025

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
423 432 430 319 570 261 252 277 210 218 177 137
328 328 323 233 319 183 184 237 182 227 365 164
Operating Profit 95 104 107 86 250 78 67 40 28 -9 -188 -27
OPM % 22% 24% 25% 27% 44% 30% 27% 14% 13% -4% -106% -20%
3 2 1 1 9 2 9 -0 6 1 0 4
Interest 30 49 64 57 59 53 53 43 42 40 36 2
Depreciation 17 18 21 19 27 18 18 17 16 17 107 18
Profit before tax 51 39 24 11 173 9 5 -21 -24 -65 -330 -44
Tax % 28% 31% 22% 28% 27% -12% -20% -8% -1% 4% -1% 0%
37 27 19 8 126 10 6 -19 -23 -68 -328 -44
EPS in Rs 4.58 3.29 2.34 1.00 15.59 1.20 0.75 -2.31 -2.81 -8.17 -39.56 -5.35
Dividend Payout % 13% 2% 0% 0% 3% 33% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -11%
5 Years: -11%
3 Years: -13%
TTM: -23%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: -30%
TTM: 88%
Stock Price CAGR
10 Years: -23%
5 Years: -17%
3 Years: -40%
1 Year: %
Return on Equity
10 Years: -7%
5 Years: -24%
3 Years: -48%
Last Year: -35%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 16 16 16 16 16 17 17 17 17 17 17 17
Reserves 330 359 358 353 545 551 556 537 508 441 117 73
444 636 698 599 571 446 348 304 323 357 377 375
165 193 231 397 229 243 234 210 247 258 286 217
Total Liabilities 955 1,203 1,303 1,365 1,361 1,255 1,155 1,067 1,095 1,072 796 681
405 397 377 387 433 405 381 356 416 429 343 326
CWIP 9 16 63 41 59 43 64 70 58 40 21 21
Investments 96 228 230 230 88 152 88 88 161 161 161 59
445 563 633 708 781 656 622 554 459 442 271 276
Total Assets 955 1,203 1,303 1,365 1,361 1,255 1,155 1,067 1,095 1,072 796 681

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
44 -45 41 -54 28 207 82 75 180 25 33 -97
-108 -149 -50 -11 30 -38 56 3 -138 -11 -2 100
58 193 9 59 -50 -175 -123 -91 -46 -13 -35 -6
Net Cash Flow -6 -0 1 -7 8 -6 15 -13 -5 1 -3 -2

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 138 155 194 264 144 234 148 118 133 106 104 159
Inventory Days 214 265 410 744 579 1,236 1,284 640 954 608 106 340
Days Payable 71 61 84 68 92 99 160 75 124 95 77 211
Cash Conversion Cycle 280 359 520 940 632 1,371 1,271 683 963 619 134 289
Working Capital Days 284 355 379 625 364 706 685 566 676 611 351 522
ROCE % 11% 10% 8% 7% 22% 6% 6% 3% 2% -3% -44% -7%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
28.57% 21.98% 20.96% 20.96% 20.96% 20.94% 20.94% 20.94% 20.94% 20.94% 20.94% 20.94%
1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64% 1.64%
0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12% 0.12%
69.67% 76.27% 77.29% 77.28% 77.29% 77.30% 77.30% 77.29% 77.30% 77.29% 77.30% 77.30%
No. of Shareholders 52,07453,11053,37652,39851,02650,68349,50349,03849,02749,01649,01249,003

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls